title: The need for routine bleomycin test dosing in the 21st century.
abstract: OBJECTIVE
  To review the clinical evidence for routine use of bleomycin test dosing.
  
  
  METHODS
  English-language review articles, references from retrieved articles, case reports, and clinical trials were identified from a MEDLINE literature search (1966-July 2005). Key search terms included bleomycin, test dose, anaphylactic reactions, and hypersensitivity. Information from an unpublished E-mail survey, the manufacturer, and the Internet was also used.
  
  
  RESULTS
  Early clinical trials and isolated case reports suggest that bleomycin-induced acute hypersensitivity reactions occur in 1% of patients with lymphoma and <0.5% of those with solid tumors. The reactions are mainly characterized by high-grade fever, chills, hypotension, and in a few cases, cardiovascular collapse, which can lead to death. The exact mechanism of these reactions is unclear, but is thought to be related to the release of endogenous pyrogens from the host cells. Evidence does not suggest any correlation between doses and the onset or severity of the reactions. Supportive care, including hydration, steroids, antipyretics, and antihistamines, may resolve the symptoms. However, it may not completely prevent recurrences.
  
  
  CONCLUSIONS
  The incidence of acute hypersensitivity or hyperpyrexic reactions associated with bleomycin is very low, but the reaction is potentially fatal. Clinicians should monitor their patients for any signs and symptoms of acute hyperpyrexic reactions during bleomycin administration. Since the onset of the reactions can occur with any dose of bleomycin and at any time, routine test dosing does not seem to predict when drug reactions may occur.
authors.affiliation: Hematology/Oncology, Shands at the University of Florida, University of Florida, PO Box 100316, Gainesville, FL 32610-0316, USA. lamsh@shands.ufl.edu
authors.forename: Masha S H
authors.initials: MS
authors.lastname: Lam
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D001761:Bleomycin / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004342:Drug Hypersensitivity / Q000209:etiology; D016903:Drug Monitoring / Q000639:trends; D005544:Forecasting; D006801:Humans
chemical_list: D000903:Antibiotics, Antineoplastic; D001761:Bleomycin